A Phase I, First-in-human, Dose-escalation Study to Evaluate the Safety and Immunologic Response After Administration of HS-130 in Combination With HS-110 (Viagenpumatucel-L) in Patients With Solid Tumors Refractory to Standard Care
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs HS 130 (Primary) ; Viagenpumatucel-L (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Heat Biologics
- 18 Oct 2019 Status changed from not yet recruiting to recruiting.
- 03 Oct 2019 Status changed from planning to not yet recruiting.
- 12 Sep 2019 According to the Heat Biologics media release, the company is planning to commence this study in the fourth quarter of 2019.